139 related articles for article (PubMed ID: 32565286)
1. Characterization of a new aerosol antibiotic/adjuvant combination for the treatment of P. aeruginosa lung infections.
Douafer H; Andrieu V; Wafo E; Brunel JM
Int J Pharm; 2020 Aug; 586():119548. PubMed ID: 32565286
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of an inhaled antibiotic/adjuvant dry powder combination using an experimental design approach.
Douafer H; Andrieu V; Wafo E; Sergent M; Brunel JM
Int J Pharm; 2021 Apr; 599():120414. PubMed ID: 33647405
[TBL] [Abstract][Full Text] [Related]
3. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
[TBL] [Abstract][Full Text] [Related]
4. Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
Chang RYK; Chen K; Wang J; Wallin M; Britton W; Morales S; Kutter E; Li J; Chan HK
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158280
[TBL] [Abstract][Full Text] [Related]
5. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
[TBL] [Abstract][Full Text] [Related]
6. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics.
Hasan MA; Lange CF
J Aerosol Med; 2007; 20(3):282-93. PubMed ID: 17894535
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
Moore JE; Mastoridis P
J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
[TBL] [Abstract][Full Text] [Related]
9. Assessment of polymyxin B-doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia.
Gaurav A; Kothari A; Omar BJ; Pathania R
Int J Antimicrob Agents; 2020 Jul; 56(1):106022. PubMed ID: 32439481
[TBL] [Abstract][Full Text] [Related]
10. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
12. Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa.
Hubble VB; Hubbard BA; Minrovic BM; Melander RJ; Melander C
ACS Infect Dis; 2019 Jan; 5(1):141-151. PubMed ID: 30444345
[TBL] [Abstract][Full Text] [Related]
13. Repurposing primaquine as a polyamine conjugate to become an antibiotic adjuvant.
Pearce AN; Chen D; Edmeades LR; Cadelis MM; Troudi A; Brunel JM; Bourguet-Kondracki ML; Copp BR
Bioorg Med Chem; 2021 May; 38():116110. PubMed ID: 33831695
[TBL] [Abstract][Full Text] [Related]
14. Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate β-lactam antibiotics against multidrug-resistant P. aeruginosa.
Ammeter D; Idowu T; Zhanel GG; Schweizer F
J Antibiot (Tokyo); 2019 Nov; 72(11):816-826. PubMed ID: 31420586
[TBL] [Abstract][Full Text] [Related]
15. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
Lin YW; Zhou QT; Han ML; Onufrak NJ; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263069
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
[TBL] [Abstract][Full Text] [Related]
18. Cospray dried antibiotics for dry powder lung delivery.
Adi H; Young PM; Chan HK; Stewart P; Agus H; Traini D
J Pharm Sci; 2008 Aug; 97(8):3356-66. PubMed ID: 17990305
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Peptide-Loaded Nanoparticles as Inhalation Therapy for
Falciani C; Zevolini F; Brunetti J; Riolo G; Gracia R; Marradi M; Loinaz I; Ziemann C; Cossío U; Llop J; Bracci L; Pini A
Int J Nanomedicine; 2020; 15():1117-1128. PubMed ID: 32110011
[TBL] [Abstract][Full Text] [Related]
20. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
